Invivo is targeting €100 million ($108.7 million) for its third fund, with an eye on European early-stage biotechs with advanced therapies such as cell therapy, gene therapy and synthetic biology.
The Barcelona-based VC has helped steer some notable exits for its portfolio companies, including Genfit’s 2022 Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
